Over the past few decades, advances in information technologies have allowed firms working to optimize their supply chains to move from decision-making on the basis of intuition and experience to more automated and data-driven methods,

The risk of a wrong product being dosed to a patient is exacerbated by a lack of standardization within the cell and gene therapy industry.

The multi-partner nature of global supply chains heightens the risk of increased vulnerabilities to cyber attack, especially if strong safeguards aren’t in place.

Since Covid-19 swept the globe, risks have spiraled, forcing governments, industry groups, nongovernmental organizations, and corporate CEOs and CFOs to rethink supply networks from the ground up. And the current threats show no sign of slowing.